Open AccessCapecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients
Author(s) -
Markus Moehler,
Martin F. Sprinzl,
Murad Abdelfattah,
Carl C. Schimanski,
Bernd Adami,
W. Gödderz,
Klaus Majer,
Dimitri Flieger,
Andreas Teufel,
Juergen Siebler,
Thomas Hoehler,
Peter R. Galle,
Stephan Kanzler
Publication year - 2009
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.15.449
Subject(s) - bevacizumab , medicine , irinotecan , capecitabine , colorectal cancer , clinical endpoint , regimen , oncology , surgery , cancer , gastroenterology , randomized controlled trial , chemotherapy
To investigate the efficacy and safety of cape-citabine plus irinotecan +/- bevacizumab in advanced or metastatic colorectal cancer patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom